secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001104659-21-112483
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma CMO resigns; new CMO appointed; updated Phase 3 data on setmelanotide
--------------------------------------------------------------------------------

- Dr. Murray Stewart resigns as CMO effective Sept 10, 2021; will serve as Senior Medical Advisor for up to one year at $12,000/month.
- Linda Shapiro Manning, M.D., Ph.D., appointed as new CMO effective Sept 10; previously SVP Clinical.
- Updated slide presentation includes new BMI reduction data from Phase 3 Bardet-Biedl syndrome trial and EMANATE powering assumptions.
- Stewart's vested options remain exercisable 3 months post-consulting; unvested options forfeited; RSUs continue vesting.
- Stewart eligible for prorated 2021 annual bonus based on employment and part-time consulting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/tm2126899d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-112483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer